Allergy

It's a Quadruple-Victory for Pets Global (Malaysia) Sdn Bhd in the 2023 Natural Health Readers' Choice Awards

Retrieved on: 
Wednesday, March 6, 2024

Four revered titles covering pet care products picked up in Natural Health Readers' Choice Awards 2023

Key Points: 
  • A first-time winner in the much-anticipated annual event, Pets Global is an independently owned, holistic wellness company which was established based on a deep-rooted concern for the welfare of animals.
  • As such, the company exercises its rights to create and produce the highest quality foods and pet-care products for our furry companions, namely cats and dogs.
  • Eric Lum, Sales & Marketing Manager of Pets Global (Malaysia) Sdn Bhd, expressed his gratitude and appreciation for the three Awards picked up by Fussie Cat.
  • Also, we always give our best in ensuring quality for all our dry food products, as with all other products from us."

First Aid Pro Launches Comprehensive First Aid Certification and CPR Training Courses

Retrieved on: 
Monday, February 19, 2024

Southport, Queensland--(Newsfile Corp. - February 19, 2024) - First Aid Pro, a leading provider of first aid and CPR training, is pleased to announce the launch of their comprehensive first aid courses and CPR Training classes that are meant to teach people and groups how to save lives.

Key Points: 
  • Southport, Queensland--(Newsfile Corp. - February 19, 2024) - First Aid Pro, a leading provider of first aid and CPR training, is pleased to announce the launch of their comprehensive first aid courses and CPR Training classes that are meant to teach people and groups how to save lives.
  • First Aid Pro recognizes the importance of such skills and is committed to delivering top-notch training to individuals and workplaces across Australia.
  • First Aid Pro offers flexible training options, including in-person courses at its training center and customized on-site training for businesses and organizations.
  • To enroll in the First Aid Certificate and CPR Training courses or learn more about First Aid Pro's offerings, please visit https://www.firstaidpro.com.au/ .

ASLAN Pharmaceuticals Provides TREK-DX Study Update and Highlights Potential of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients

Retrieved on: 
Monday, March 11, 2024

In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.

Key Points: 
  • In conjunction with this, independent reviewer confirmation of baseline EASI scores has also been implemented.
  • Of the 9 patients who previously had an inadequate response to dupilumab, 5 patients (56%) achieved EASI-90 and 5 patients (56%) a vIGA score of 0 or 1.
  • Additional data from head-to-head studies between eblasakimab and dupilumab in skin biopsies from AD patients confirmed the differentiated effects of targeting IL-13R versus IL-4R5.
  • In this study, eblasakimab reduced localized secretion of pro-inflammatory Type 2 cytokines by the skin tissue more efficiently than dupilumab, suggesting eblasakimab could have the potential to be effective in AD patients that do not achieve an adequate response to dupilumab.

Stonewall Kitchen Issues Allergy Alert for Wheat in Limited Quantity of Gluten Free Cinnamon Sugar Doughnut Mix

Retrieved on: 
Thursday, March 7, 2024

YORK, Maine, March 07, 2024 (GLOBE NEWSWIRE) -- Stonewall Kitchen of York, Maine is voluntarily recalling a limited amount of their Gluten Free Cinnamon Sugar Doughnut Mix because it may contain an undeclared allergen, wheat.

Key Points: 
  • YORK, Maine, March 07, 2024 (GLOBE NEWSWIRE) -- Stonewall Kitchen of York, Maine is voluntarily recalling a limited amount of their Gluten Free Cinnamon Sugar Doughnut Mix because it may contain an undeclared allergen, wheat.
  • People who have an allergy or severe sensitivity to wheat (which contains gluten) may risk serious allergic reaction if they consume this product from impacted lots listed below.
  • A limited quantity of this product was distributed nationwide to consumers through Stonewall Kitchen’s retail stores, stonewallkitchen.com and through third-party wholesale customers such as specialty grocers, department stores, or gourmet food shops.
  • Consumers should contact Stonewall Kitchen Premier Guest Services by email at [email protected] or by phone at 800-826-1735, Monday-Friday: 8:00am to 5:00pm EST.

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

Retrieved on: 
Thursday, March 7, 2024

The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.

Key Points: 
  • The event included presentations by members of the ARS Pharma management team and by two distinguished allergists, Dr. Jonathan Spergel, M.D., Ph.D. and Dr. Thomas B. Casale, M.D.
  • Of the patients that do fill their prescription, 80-90% either do not carry or use their treatment as indicated.
  • In late-February, the Company announced positive clinical data from a Phase 2 trial evaluating neffy in adults with chronic spontaneous urticaria.
  • The webcast replay and accompanying slides from today’s investor event may be accessed through the Events & Presentations page in the Investors & Media section of the Company's website.

Latitude Food Allergy Care Announces the Opening of its New San Francisco Clinic; Pacific Heights Clinic is the First-of-its-Kind and Only Clinic in San Francisco Specifically Dedicated to Food Allergy Patients

Retrieved on: 
Wednesday, March 6, 2024

As the only clinic in San Francisco dedicated to food allergies, the new space allows Latitude to expand its hours to provide care for more families.

Key Points: 
  • As the only clinic in San Francisco dedicated to food allergies, the new space allows Latitude to expand its hours to provide care for more families.
  • As with all of Latitude's clinics, the newly built clinic is designed specifically for the needs of food allergy patients and their caregivers.
  • The bright, family room-like setting allows patients to connect with other food allergy families that are going through similar experiences.
  • “We are delighted to welcome two exceptional doctors to the Latitude Food Allergy Care family to expand access to life-changing food allergy care in the San Francisco Bay Area,” said Dr. Rani Maskatia, Medical Director of Latitude Food Allergy Care.

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

Retrieved on: 
Wednesday, March 6, 2024

SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 being held March 11-13, 2024 in Miami, Florida.

Key Points: 
  • SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced its participation in the Leerink Partners Global Biopharma Conference 2024 being held March 11-13, 2024 in Miami, Florida.
  • Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma and Eric Karas, Chief Commercial Officer of ARS Pharma will participate in a fireside chat on Wednesday, March 13, 2024, at 10:00 a.m.
  • A live webcast of the fireside chat will be available here and in the Investors & Media section of the Company’s website.
  • A replay of the webcast will be archived on the Company’s website for 90 days.

Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, March 5, 2024

Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.

Key Points: 
  • Aquestive received positive feedback in October 2023 from the U.S. Food and Drug Administration (FDA) on the Company's pivotal Phase 3 Pharmacokinetic (PK) clinical protocol for Anaphylm.
  • Aquestive commenced dosing in December 2023 in the Phase 3 pivotal PK clinical study of Anaphylm.
  • Non-GAAP adjusted EBITDA loss was $2.8 million in the fourth quarter 2023, compared to a $9.6 million loss in the fourth quarter 2022.
  • During the fourth quarter 2023, the Company accessed capital net proceeds of $3.7 million under its "At-the-Market" (ATM) facility.

Tiny Health, Pioneer of the First At-Home Baby Gut Microbiome Test, Aims to Address the Pediatric Chronic Conditions Crisis

Retrieved on: 
Tuesday, March 5, 2024

The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.

Key Points: 
  • The partnership enables Tiny Health to continue trailblazing the gut health testing category and avert the pediatric chronic conditions crisis.
  • Families are facing a pediatric chronic conditions crisis, with increasing rates of eczema, asthma, diabetes, obesity, food allergies, ADHD, autoimmune diseases, and more.
  • I founded Tiny Health to bridge the gap in the market, help address the pediatric chronic conditions crisis, and empower families to take a proactive approach to their lifelong health.
  • Since its inception, Tiny Health has pioneered the family gut testing category including:
    Established the first, at-home gut microbiome test for babies.

Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Monday, March 4, 2024

“2023 was a highly productive year for Jasper, as we shifted our operational focus toward briquilimab development in mast cell driven diseases,” said Ronald Martell, President and Chief Executive Officer.

Key Points: 
  • “2023 was a highly productive year for Jasper, as we shifted our operational focus toward briquilimab development in mast cell driven diseases,” said Ronald Martell, President and Chief Executive Officer.
  • Obtained regulatory clearance in the US and EU for initiation of its Phase 1b/2a BEACON study of subcutaneous briquilimab in CSU.
  • Jasper expects to report initial data from at least the first four cohorts of the study in the third quarter of 2024.
  • Jasper expects to conduct the study across four clinical sites in the EU and has activated three sites to date.